BioMedNewsBreaks

WednesdayMay 27, 2026 11:30 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio 

VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use. To view the full press release, visit https://ibn.fm/nX9FK About Volition Volition is a multi-national company focused on…

Continue Reading

WednesdayMay 27, 2026 11:23 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Gains DTC Eligibility, Engages IBN for Investor Awareness Campaign

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.  Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company, a move expected to simplify trading for U.S. investors and enhance liquidity of the company’s shares. CEO Louis Dron said DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement. The company also announced it has engaged InvestorBrandNetwork to provide market awareness, corporate communications and digital media services, including editorial coverage, newsletter distribution, social media support and podcast syndication through Sept. 30, 2026,…

Continue Reading

WednesdayMay 27, 2026 10:36 am

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company’s position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales. The commissioned report cites Optimi’s regulatory licenses, existing MDMA and psilocybin manufacturing capacity, expanding commercial activity in Australia and longer-term U.S. optionality, while outlining an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi’s asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development…

Continue Reading

WednesdayMay 27, 2026 9:30 am

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes. To view the full press release, visit https://ibn.fm/qFRHu About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes…

Continue Reading

TuesdayMay 26, 2026 11:46 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Collaborates with Resilience Biosciences on AI-Driven Drug Discovery 

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.  Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced a collaboration with Resilience Biosciences Inc. to support the development and evaluation of AI-assisted computational chemistry workflows for small-molecule drug development, with the goal of improving efficiency in identifying, analyzing and advancing potential drug candidates. The collaboration will apply Redwood’s computational chemistry, cheminformatics and synthetic route design capabilities to support Resilience’s non-opioid therapeutic development programs, including workflows for derivative generation, patentability and freedom-to-operate analysis, and retrosynthetic planning aimed at accelerating early-stage drug discovery and development. To view the full press release, visit https://ibn.fm/CmioF About Redwood AI Corp. Redwood…

Continue Reading

TuesdayMay 26, 2026 11:25 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Advances Manufacturing Scale-Up for Lead Oncology Candidate ONC010 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) reported continued progress in intermediate-scale manufacturing and process development activities for key precursor components supporting ONC010, the company’s lead nanoparticle-formulated oncology candidate currently advancing through IND-enabling development. The work, being conducted with Dalton Pharma Services as part of Onco’s integrated chemistry, manufacturing and controls strategy, is focused on process optimization, analytical characterization and manufacturing reproducibility to support future GMP production, regulatory readiness and planned first-in-human clinical development activities in Australia. To view the full press release, visit https://ibn.fm/Unt8n About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer…

Continue Reading

FridayMay 22, 2026 3:28 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,”…

Continue Reading

ThursdayMay 21, 2026 12:55 pm

BioMedNewsBreaks — Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments,” a recent article reads. “Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic.…

Continue Reading

ThursdayMay 21, 2026 11:08 am

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Launches MyndSystem Cognitive Support Platform 

BioAdaptives (OTC: BDPT) a science-driven health and wellness company, announced the launch of MyndSystem, a dual-phase cognitive support platform combining its daytime MyndMed formula with newly released nighttime recovery product MyndRenew into a 24-hour stimulant-free cognitive support system. The company said MyndSystem was originally developed for professional combat athletes and is designed to address both daytime mental performance and overnight neural recovery. MyndMed is a 12-ingredient daytime formula intended to support focus, mental clarity and cognitive endurance, while MyndRenew is a 14-ingredient nighttime formula designed to support the brain’s overnight repair processes, according to the company. BioAdaptives said the complete MyndSystem platform is now available for purchase as a 30-day supply through direct purchase or subscription. To view…

Continue Reading

WednesdayMay 20, 2026 2:01 pm

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering 

Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses through the sale of 12 million common units, each including common stock or pre-funded warrants and two Series C warrants. The company said net proceeds will be used for general corporate purposes and working capital, with potential additional gross proceeds of approximately $12 million if the Series C warrants are fully exercised for cash, while Aegis Capital acted as exclusive placement agent. To view the full press release, visit https://ibn.fm/1acV7 About Sunshine Biopharma Inc. Sunshine Biopharma currently markets 60 generic prescription drugs in…

Continue Reading